Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

NCT00217503 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

NIH

Sponsor class

Conditions

Lymphoma

Interventions

BIOLOGICAL: bevacizumab
BIOLOGICAL: filgrastim
BIOLOGICAL: pegfilgrastim
DRUG: bortezomib
DRUG: cyclophosphamide
DRUG: doxorubicin hydrochloride
DRUG: etoposide
DRUG: ganciclovir
DRUG: valganciclovir
DRUG: zidovudine

Sponsor

National Cancer Institute (NCI)